Loading...
Loading...
Astellas Pharma
ALPMY and Medivation
MDVN
today announced that Astellas has submitted an application for marketing
approval of enzalutamide (generic name) to the Ministry of Health,
Labour and Welfare in Japan for the treatment of prostate cancer.
Enzalutamide is a novel, once-daily, oral androgen receptor signaling
inhibitor. It inhibits multiple steps in the androgen receptor signaling
pathway, which has been shown to decrease cancer cell growth and can
induce cancer cell death (apoptosis).
This filing application is based mainly on results obtained from the
global Phase 3 trial (the AFFIRM trial)* and a Phase 1-2 trial conducted
in Japan.**
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in